Abbvie ((ABBV)), Genmab (Otc) ((GMAB)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The recent clinical study update from AbbVie and Genmab focuses on evaluating the efficacy and safety of Epcoritamab, with or without Lenalidomide, as a first-line treatment for elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who are ineligible for anthracycline therapy. Officially titled ‘Efficacy and Safety of Epcoritamab Monotherapy and in Combination With Lenalidomide as First-line Therapy for Anthracycline-ineligible Diffuse Large B-Cell Lymphoma Patients,’ this Phase 2 trial aims to provide alternative therapeutic options for this patient demographic.
The interventions being tested include Epcoritamab, a biological agent administered via subcutaneous injections, and Lenalidomide, an oral drug. Epcoritamab is being evaluated both as a standalone treatment and in combination with Lenalidomide, with the goal of improving patient outcomes.
This open-label, randomized, multicenter, global study employs a parallel intervention model with no masking. Its primary purpose is treatment, and it is structured in two stages: an initial safety run-in phase followed by an expansion phase.
The study began on March 6, 2023, with primary completion expected by August 4, 2025. These dates are crucial for tracking the study’s progress and evaluating its impact on future treatment protocols.
The market implications of this study are significant for both AbbVie and Genmab, as positive results could enhance their competitive position in the oncology market and potentially boost investor confidence. The study’s outcome could also affect stock performance, especially in comparison to competitors in the DLBCL treatment space.
The study is ongoing, and further details are available on the ClinicalTrials portal.